Cardiovascular Research

Invasive versus Conservative Management in Coronary Artery Disease.

Authors: Shereif H Rezkalla|||Robert A Kloner

Affiliations: + Expand

Abstract

In patients with ST-elevation myocardial infarction, immediate coronary angiography and intervention is the best practice, if an experienced laboratory is available. In non-Q-wave infarction most, but not all, studies suggest that early invasive strategy is superior to conservative management. Complete revascularization is preferred. A literature search regarding management of coronary artery disease was conducted in PubMed between January 1985 to January 2021. Articles published in English were reviewed, and those relevant were selected by both authors. Special focus was on the ISCHEMIA trial and related articles. The utility of coronary angiography in patients with stable coronary artery disease is challenging. All patients should undergo optimal medical therapy. Patients with angina should not only receive approved anti-anginal agents but should also receive lifestyle modifications and pharmacologic therapy to control risk factors such as diabetes, hypertension, dyslipidemia, and smoking; and should consider organized physical activity programs. Low density lipoprotein should be reduced to 70 mg/dL or less. Non-invasive studies such as coronary computed tomography angiography (CCTA) are preferred. If expert CCTA is not available, then stress test, preferably with imaging, is recommended. If the results of CCTA show high risk, then coronary angiography and intervention are usually indicated. In patients with left main disease, left ventricular dysfunction, or symptoms of congestive heart failure, early invasive strategy is recommended. If none of these conditions exist, then initial medical therapy may be initiated, and invasive therapy should be utilized only if clinically indicated. In patients with chronic stable angina, continue with medical therapy and risk factor modification. If the frequency or severity of angina episodes change, coronary angiography and revascularization should be considered, as appropriate. In patients with significant renal dysfunction, angiogram may be indicated only if there is complete failure of medical therapy. Optimal medical therapy should be initially utilized in all patients. Early invasive management and revascularization should be utilized in patients with left ventricular dysfunction, congestive heart failure, and failure of medical therapy. A shared decision-making process should always be utilized.

---

Reference List

Bourassa MG. The history of cardiac catheterization. Can J Cardiol. 2005;21(12):1011-1014.|||Ryan TJ. The coronary angiogram and its seminal contributions to cardiovascular medicine over five decades. Circulation. 2002;106(6):752-756. doi:10.1161/01.CIR.0000024109.12658.D4.|||DeWood MA, Spores J, Notske R, et al. . Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303(16):897-902. doi:10.1056/NEJM198010163031601.|||Braunwald E. The treatment of acute myocardial infarction: the Past, the Present, and the Future. Eur Heart J Acute Cardiovasc Care. 2012;1(1):9-12. doi:10.1177/2048872612438026.|||O’Neill W, Timmis GC, Bourdillon PD, et al. . A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med. 1986;314(13):812-818. doi:10.1056/NEJM198603273141303.|||Maron DJ, Hochman JS, Reynolds HR, et al. ; ISCHEMIA Research Group . Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395-1407. doi:10.1056/NEJMoa1915922.|||Moon JCC, Kalra PR, Coats AJS.. DANAMI-2: Is primary angioplasty superior to thrombolysis in acute MI when the patient has to be transferred to an invasive centre? Int J Cardiol. 2002;85(2-3):199-201. doi:10.1016/S0167-5273(02)00183-3.|||Bøhmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S.. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol. 2010;55(2):102-110. doi:10.1016/j.jacc.2009.08.007.|||TIMI Study Group . Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med. 1989;320(10):618-627. doi:10.1056/NEJM198903093201002|||Grines CL, Browne KF, Marco J, et al. ; The Primary Angioplasty in Myocardial Infarction Study Group . A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1993;328(10):673-679. doi:10.1056/NEJM199303113281001|||Grines CL, Cox DA, Stone GW, et al. ; Stent Primary Angioplasty in Myocardial Infarction Study Group . Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med. 1999;341(26):1949-1956. doi:10.1056/NEJM199912233412601.|||Topol EJ. A guide to therapeutic decision-making in patients with non–ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2003;41(4)(Suppl S):S123-S129. doi:10.1016/S0735-1097(02)02689-X.|||Fox KAA, Clayton TC, Damman P, et al. ; FIR Collaboration . Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol. 2010;55(22):2435-2445. doi:10.1016/j.jacc.2010.03.007.|||Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. 1999;354(9180):708-715.|||Cannon CP, Weintraub WS, Demopoulos LA, et al. ; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)—Thrombolysis in Myocardial Infarction 18 Investigators . Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344(25):1879-1887. doi:10.1056/NEJM200106213442501.|||Fox KAA, Poole-Wilson PA, Henderson RA, et al. ; Randomized Intervention Trial of unstable Angina Investigators . Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. 2002;360(9335):743-751. doi:10.1016/S0140-6736(02)09894-X.|||Milosevic A, Vasiljevic-Pokrajcic Z, Milasinovic D, et al. . Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients: The RIDDLE-NSTEMI Study. JACC Cardiovasc Interv. 2016;9(6):541-549. doi:10.1016/j.jcin.2015.11.018.|||Milasinovic D, Milosevic A, Vasiljevic-Pokrajcic Z, et al. . Three-Year Impact of Immediate Invasive Strategy in Patients With Non–ST-Segment Elevation Myocardial Infarction (from the RIDDLE-NSTEMI Study). Am J Cardiol. 2018;122(1):54-60. doi:10.1016/j.amjcard.2018.03.006.|||Mehta SR, Cannon CP, Fox KAA, et al. . Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005;293(23):2908-2917. doi:10.1001/jama.293.23.2908.|||Badings EA, The SHK, Dambrink JHE, et al. . Early or late intervention in high-risk non-ST-elevation acute coronary syndromes: results of the ELISA-3 trial. EuroIntervention. 2013;9(1):54-61. doi:10.4244/EIJV9I1A9.|||Thiele H, Rach J, Klein N, et al. . Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI (LIPSIA-NSTEMI Trial). Eur Heart J. 2012;33(16):2035-2043. doi:10.1093/eurheartj/ehr418|||Montalescot G, Cayla G, Collet JP, et al. . Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA. 2009;302(9):947-954. doi:10.1001/jama.2009.1267|||Mehta SR, Granger CB, Boden WE, et al. . Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360(21):2165-2175. doi:10.1056/NEJMoa0807986|||Mahoney EM, Jurkovitz CT, Chu H, et al. . Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002;288(15):1851-1858. doi:10.1001/jama.288.15.1851|||Hoedemaker NPG, Damman P, Woudstra P, et al. . Early Invasive Versus Selective Strategy for Non-ST-Segment Elevation Acute Coronary Syndrome: The ICTUS Trial. J Am Coll Cardiol. 2017;69(15):1883-1893. doi:10.1016/j.jacc.2017.02.023|||Hirsch A, Windhausen F, Tijssen JG, et al. . Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. Lancet. 2007;369(9564):827-835. doi:10.1016/S0140-6736(07)60410-3|||Damman P, Hirsch A, Windhausen F, Tijssen JG, de Winter RJ; ICTUS Investigators . 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2010;55(9):858-864. doi:10.1016/j.jacc.2009.11.026|||Puymirat E, Taldir G, Aissaoui N, et al. . Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome). JACC Cardiovasc Interv. 2012;5(9):893-902. doi:10.1016/j.jcin.2012.05.008|||de Winter RJ, Windhausen F, Cornel JH, et al. . Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005;353(11):1095-1104. doi:10.1056/NEJMoa044259|||Sharma A, Coles A, Ksearan NK, et al. . Stress testing versus CT angiography in patients with diabetes and suspected coronary artery disease. J Am Coll Cardiol. 2019;73(8):893-902. doi:10.1016/j.jacc.2018.11.056|||Kunniardy P, Koshy AN, Meehan G, et al. . Invasive versus conservative management in patients ≥85 years presenting with non-ST elevation myocardial infarction Intern Med J. 2021;10.1111/imj.15258. doi:10.1111/imj.15258|||de Belder A, Myat A, Blaxill J, et al. . Revascularisation or medical therapy in elderly patients with acute anginal syndromes: the RINCAL randomised trial. EuroIntervention. 2021;17(1):67-74. doi:10.4244/EIJ-D-20-00975|||Kolte D, Khera S, Palaniswamy C, et al. . Early invasive versus initial conservative treatment strategies in octogenarians with UA/NSTEMI. Am J Med. 2013;126(12):1076-83.e1. doi:10.1016/j.amjmed.2013.07.024|||Reinius P, Mellbin L, Holzmann MJ, Siddiqui AJ.. Percutaneous coronary intervention versus conservative treatment for non ST-segment elevation myocardial infarction in patients above 80 years of age. Int J Cardiol. 2018;267:57-61. doi:10.1016/j.ijcard.2018.05.078|||Tegn N, Abdelnoor M, Aaberge L, et al. . Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet. 2016;387(10023):1057-1065. doi:10.1016/S0140-6736(15)01166-6|||Sanchis J, Núñez E, Barrabés JA, et al. . Randomized comparison between the invasive and conservative strategies in comorbid elderly patients with non-ST elevation myocardial infarction. Eur J Intern Med. 2016;35:89-94. doi:10.1016/j.ejim.2016.07.003|||Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in J Am Coll Cardiol. 2022 Apr 19;79(15):1547]. J Am Coll Cardiol. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006|||TIME Investigators . Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet. 2001;358(9286):951-957. doi:10.1016/S0140-6736(01)06100-1|||Bairey Merz CN, Shaw LJ, Reis SE, et al. . Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. 2006;47(3 Suppl):S21-S29. doi:10.1016/j.jacc.2004.12.084|||O’Donoghue M, Boden WE, Braunwald E, et al. . Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008;300(1):71-80. doi:10.1001/jama.300.1.71|||Sui YG, Teng SY, Qian J, et al. . Gender differences in treatment strategies among patients ≥80 years old with non-ST-segment elevation myocardial infarction. J Thorac Dis. 2019;11(12):5258-5265. doi:10.21037/jtd.2019.11.55|||Lee LC, Poh KK, Tang TP, Tan YL, Tee HW, Tan HC.. The impact of gender on the outcomes of invasive versus conservative management of patients with non-ST-segment elevation myocardial infarction. Ann Acad Med Singap. 2010;39(3):168-172.|||Fihn SD, Gardin JM, Abrams J, et al. . 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons [published correction appears in Circulation. 2014 Apr 22;129(16):e462]. Circulation. 2012;126(25):3097-3137. doi:10.1161/CIR.0b013e3182776f83|||Boden WE, O’Rourke RA, Teo KK, et al. . Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-1516. doi:10.1056/NEJMoa070829|||BARI 2D Study Group, Frye RL, August P, et al. . A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503-2515. doi:10.1056/NEJMoa0805796|||Bangalore S, Maron DJ, Stone GW, Hochman JS.. Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials. Circulation. 2020;142(9):841-857. doi:10.1161/CIRCULATIONAHA.120.048194|||Maron DJ, Hochman JS, Reynolds HR, et al. . Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395-1407. doi:10.1056/NEJMoa1915922|||Lopes RD, Alexander KP, Stevens SR, et al. . Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial [published correction appears in Circulation. 2020 Oct 13;142(15):e236]. Circulation. 2020;142(18):1725-1735. doi:10.1161/CIRCULATIONAHA.120.050304|||Lopez-Sendon J, Moreno R, Tamargo J.. ISCHEMIA Trial: Key Questions and Answers. Eur Cardiol. 2021;16:e34. doi:10.15420/ecr.2021.16|||Murthy VL, Bateman TM, Chen W, et al. . Impact of the ISCHEMIA Trial on Stress Nuclear Myocardial Perfusion Imaging. J Nucl Med. 2020;61(7):962-964. doi:10.2967/jnumed.119.245399|||Hochman JS, Reynolds HR, Bangalore S, et al. . Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial [published correction appears in JAMA Cardiol. 2019 May 1;4(5):497]. JAMA Cardiol. 2019;4(3):273-286. doi:10.1001/jamacardio.2019.0014|||Reynolds HR, Shaw LJ, Min JK, et al. . Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity. Circulation. 2021;144(13):1024-1038. doi:10.1161/CIRCULATIONAHA.120.049755|||Mavromatis K, Boden WE.. What is the Real Message of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial for Academic and Practising Cardiologists? Eur Cardiol. 2020;15:e64. doi:10.15420/ecr.2020.26|||Spertus JA, Jones PG, Maron DJ, et al. . Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N Engl J Med. 2020;382(15):1408-1419. doi:10.1056/NEJMoa1916370|||Mavromatis K, Gershlick A.. The Impact of the ISCHEMIA Trial on Clinical Practice: an Interventionist’s Perspective. Cardiovasc Drugs Ther. 2021;10.1007/s10557-021-07230-x. doi:10.1007/s10557-021-07230-x|||Chaitman BR, Alexander KP, Cyr DD, et al. . Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. Circulation. 2021;143(8):790-804. doi:10.1161/CIRCULATIONAHA.120.047987|||Spertus JA, Jones PG, Maron DJ, et al. . Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. N Engl J Med. 2020;382(17):1619-1628. doi:10.1056/NEJMoa1916374|||Bangalore S, Maron DJ, O’Brien SM, et al. . Management of Coronary Disease in Patients with Advanced Kidney Disease. N Engl J Med. 2020;382(17):1608-1618. doi:10.1056/NEJMoa1915925|||Herzog CA, Simegn MA, Xu Y, et al. . Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial. J Am Coll Cardiol. 2021;78(4):348-361. doi:10.1016/j.jacc.2021.05.001|||Alexander JH, Smith PK.. Are We At Risk of Depriving Patients Lifesaving Cardiac Surgery?: Implications of the ISCHEMIA Trial for Coronary Artery Bypass Graft Surgery. Circulation. 2020;142(19):1797-1798. doi:10.1161/CIRCULATIONAHA.120.050524|||Hanson CA, Patel TR, Villines TC.. The New Role of Cardiac Imaging Following the ISCHEMIA Trial. Curr Treat Options Cardiovasc Med. 2021;23(6):23. doi:10.1007/s11936-021-00911-8|||Mancini GBJ, Leipsic J, Budoff MJ, et al. . CT Angiography Followed by Invasive Angiography in Patients With Moderate or Severe Ischemia-Insights From the ISCHEMIA Trial [published correction appears in JACC Cardiovasc Imaging. 2021 Jun;14(6):1296]. JACC Cardiovasc Imaging. 2021;14(7):1384-1393. doi:10.1016/j.jcmg.2020.11.012|||Smolka S, Desai MY, Achenbach S.. After ISCHEMIA: Is coronary CTA the new gatekeeper? ISCHEMIA-Studie: Stellt die koronare CT-Angiographie künftig die Weichen? Herz. 2020;45(5):441-445. doi:10.1007/s00059-020-04962-8|||DISCHARGE Trial Group, Maurovich-Horvat P, Bosserdt M, et al. . CT or Invasive Coronary Angiography in Stable Chest Pain. N Engl J Med. 2022;386(17):1591-1602. doi:10.1056/NEJMoa2200963|||SCOT-HEART Investigators, Newby DE, Adamson PD, et al. . Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med. 2018;379(10):924-933. doi:10.1056/NEJMoa1805971|||Money JE, Muhlestein JB, Mason S, et al. . Simplifying the ISCHEMIA trial algorithm for clinical practice: Identifying left main coronary artery disease using coronary artery calcium scans. Am Heart J. 2021;239:129-134. doi:10.1016/j.ahj.2021.05.013|||Vij A, Kassab K, Chawla H, et al. . Invasive therapy versus conservative therapy for patients with stable coronary artery disease: An updated meta-analysis. Clin Cardiol. 2021;44(5):675-682. doi:10.1002/clc.23592|||Patel MR, Nørgaard BL, Fairbairn TA, et al. . 1-Year Impact on Medical Practice and Clinical Outcomes of FFRCT: The ADVANCE Registry. JACC Cardiovasc Imaging. 2020;13(1 Pt 1):97-105. doi:10.1016/j.jcmg.2019.03.003|||Lopes RD, Alexander KP, Hochman JS, Maron DJ.. Response by Lopes et al to Letter Regarding Article, “Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial”. Circulation. 2021;143(20):e961-e962. doi:10.1161/CIRCULATIONAHA.121.053672|||Avanzas P, Kaski JC.. The ISCHEMIA Trial: And the Winner Is… the Patient. Eur Cardiol. 2021;16:e10. doi:10.15420/ecr.2021.03|||Schwarzman L, Miron-Shatz T, Maki K, et al. . Shared Decision-Making in Femoral Versus Radial Cardiac Catheterization. Am J Cardiol. 2019;124(2):190-194. doi:10.1016/j.amjcard.2019.04.014|||Vafaei P, Naderi S, Ambrosy AP, Slade JJ.. Implications of the Landmark ISCHEMIA Trial on the Initial Management of High-Risk Patients with Stable Ischemic Heart Disease. Curr Atheroscler Rep. 2021;23(11):70. doi:10.1007/s11883-021-00970-z